首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126417

癲癇診斷市場－策略分析與預測（2026-2035）

Epilepsy Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計癲癇診斷市場將從 2026 年的 82.9 億美元成長到 2035 年的 188.8 億美元，複合年成長率為 9.6%。

全球癲癇診斷市場正經歷重大變革，其驅動力來自技術進步以及對早期精準診斷日益成長的重視。該市場涵蓋了廣泛的產品，包括醫療設備、影像系統、分子診斷測試、穿戴式監測技術和臨床軟體。醫療專業人員正擴大採用整合腦電圖 (EEG)、神經影像和基因檢測的多模態診斷方法，以提高不同患者群體的診斷準確性。全球約有 5000 萬人患有癲癇，其日益成長的全球負擔催生了對先進診斷解決方案的持續需求。人工智慧 (AI) 透過自動化腦電圖分析和在緊急情況下協助神經科，正在改變臨床工作流程。這些結構性變化，加上國家醫療保險對神經系統疾病和診斷程序的覆蓋範圍不斷擴大，正在鞏固癲癇診斷作為現代神經醫療保健重要組成部分的地位。

市場促進因素

全球癲癇患者人數不斷增加，對診斷的需求也隨之增加。

癲癇仍然是全球最常見的神經系統疾病之一，因此對精準診斷評估的需求持續存在。醫療機構正在不斷提升診斷能力，因為早期發現可以減少治療延誤，並改善癲癇的長期管理。臨床路徑越來越依賴客觀的神經生理學證據，以此作為啟動長期抗癲癇治療的依據。醫院也正在投資建造最先進的腦電圖（EEG）基礎設施，以應對神經科日益成長的工作量。這些趨勢共同推動了對全面癲癇診斷的持續需求。

人工智慧驅動的腦電圖（EEG）分析正在改變臨床工作流程。

腦電圖（EEG）仍然是癲癇診斷的基石，因為它能夠直接記錄大腦中的異常電活動。隨著患者數量的增加，神經科醫師解讀長期腦電圖記錄的負擔也日益加重。製造商正在整合機器學習演算法，以自動識別癲癇發作模式並優先處理具有臨床意義的記錄。醫療機構正在採用這些平台來簡化工作流程並加速治療決策。腦電圖記錄的自動解讀不僅提高了診斷的一致性，還有助於緩解神經科這一高需求領域專家的短缺問題。美國食品藥物管理局（FDA）近期批准用於癲癇發作檢測的人工智慧軟體，就充分體現了這項技術進步。

精準醫療的擴展正推動分子診斷技術的日益普及。

由於遺傳性癲癇綜合症需要針對性的臨床管理，因此，關於癲癇的遺傳學知識持續影響診斷實踐。神經科醫生擴大將分子檢測納入兒童癲癇和複雜癲癇病例的綜合診斷流程中。診斷檢測實驗室正在擴展其基因組檢測能力，以識別與治療反應和疾病預後相關的致病突變。早期分子診斷有助於制定個人化的治療方案和進行家庭諮詢。因此，精準診斷正成為現代癲癇治療中日益重要的一環。

重症神經病學的進步推動了連續腦電圖（EEG）監測的應用。

在加護病房，常會遇到意識障礙但無明顯臨床表現的癲癇發作患者。由於僅憑床邊觀察往往難以發現非驚厥性癲癇發作，因此，持續腦電圖（EEG）監測已成為許多高風險神經系統疾病患者的標準診療手段。醫院正在採用攜帶式監測系統，以便在急診和重症監護環境中快速進行神經系統評估。早期辨識癲癇發作有助於掌握治療時機，減少神經系統併發症。這些臨床進展持續推動對攜帶式腦電圖平台和自動化監測解決方案的需求。

市場限制因素

維修成本限制了其在小規模醫院和資源有限的醫療系統中的應用。訓練有素的癲癇專科醫生和腦電圖技師數量有限，阻礙了先進診斷技術的有效利用。高階神經影像學、長期腦電圖監測和基因檢測的報銷政策差異，延緩了這些技術在臨床實踐中的廣泛應用。此外，將新的診斷技術整合到現有醫院資訊系統中的複雜性也可能造成營運障礙。

依產品
- 腦電圖（EEG）系統
- 磁振造影（MRI）
- 電腦斷層掃描（CT）
- 正子斷層掃描（PET）
- 單光子發射電腦斷層掃描（SPECT）
- 磁腦電圖（MEG）
- 分子和基因診斷檢測
- 穿戴式和攜帶式監測設備
透過診斷技術
- 神經影像學
- 電生理診斷
- 分子診斷
- 基於數位/人工智慧的診斷技術
癲癇的類型
- 局部性癲癇
- 整體癲癇
- 整體癲癇和局部性癲癇同時發生
- 病因不明的癲癇
按年齡層
- 兒童
- 成人
- 老年人
最終用戶
- 醫院
- 神經內科診所
- 診斷影像中心
- 學術研究機構
- 門診手術中心

第10章：全球癲癇診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球癲癇診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

GE HealthCare
Siemens Healthineers AG
Koninklijke Philips NV
Nihon Kohden Corporation
Natus Medical Incorporated
Compumedics Limited
Cadwell Industries, Inc.
Masimo Corporation
EGI（Electrical Geodesics, Inc.）
Neurosoft
Micromed SpA
CERIBELL, Inc.
Medtronic plc
Canon Medical Systems Corporation
Fujifilm Healthcare Corporation

第14章全球癲癇診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009128

The Epilepsy Diagnostics Market is anticipated to grow at a CAGR of 9.6% from USD 8.29 billion in 2026 to USD 18.88 billion in 2035.

The global epilepsy diagnostics market is undergoing a significant transformation, driven by technological advancements and a growing emphasis on early and accurate diagnosis. This market encompasses a comprehensive range of medical devices, imaging systems, molecular diagnostic tests, wearable monitoring technologies, and clinical software. Healthcare providers are increasingly adopting a multimodal diagnostic approach, integrating electroencephalography (EEG), neuroimaging, and genetic testing to improve diagnostic confidence across diverse patient populations. The rising global burden of epilepsy, affecting approximately 50 million people worldwide, is creating sustained demand for advanced diagnostic solutions. Artificial intelligence is reshaping clinical workflows by automating EEG interpretation and supporting neurologists in emergency settings. These structural changes, coupled with national neurological strategies and expanding reimbursement for neurodiagnostic procedures, position epilepsy diagnostics as a critical component of modern neurological care.

Market Drivers

Rising Global Burden of Epilepsy Is Expanding Diagnostic Demand

Epilepsy remains one of the world's most common neurological disorders, creating sustained demand for accurate diagnostic evaluation. Healthcare providers are expanding diagnostic capacity because earlier identification reduces treatment delays and improves long-term seizure management. Clinical pathways increasingly depend on objective neurophysiological evidence before initiating long-term antiseizure therapy. Hospitals are investing in modern EEG infrastructure to support growing neurological workloads. These developments reinforce sustained demand for comprehensive epilepsy diagnostics.

AI-Assisted EEG Interpretation Is Transforming Clinical Workflow

Electroencephalography remains the foundation of epilepsy diagnosis because it directly records abnormal cerebral electrical activity. Growing patient volumes are increasing pressure on neurologists responsible for interpreting prolonged EEG recordings. Manufacturers are integrating machine-learning algorithms that automatically identify seizure patterns and prioritize clinically significant recordings. Healthcare institutions are adopting these platforms to improve workflow efficiency and accelerate treatment decisions. Automated EEG interpretation strengthens diagnostic consistency while supporting specialist shortages in high-demand neurological settings. Recent FDA clearances for AI-enabled seizure detection software illustrate this technological progression.

Expansion of Precision Medicine Is Increasing Molecular Diagnostic Adoption

Genetic understanding of epilepsy continues to influence diagnostic practice because inherited epileptic syndromes require targeted clinical management. Neurologists increasingly incorporate molecular testing into comprehensive diagnostic pathways for pediatric and complex epilepsy cases. Diagnostic laboratories are expanding genomic testing capabilities to identify pathogenic variants associated with treatment response and disease prognosis. Earlier molecular diagnosis supports personalized therapeutic decisions and family counseling. Precision diagnostics therefore represent an increasingly important component of modern epilepsy care.

Growth of Critical Care Neurology Is Supporting Continuous EEG Monitoring

Intensive care units frequently manage patients with altered consciousness where seizures remain clinically silent. Continuous EEG monitoring is becoming standard practice for many high-risk neurological patients because bedside observation alone often fails to detect non-convulsive seizure activity. Hospitals are deploying portable monitoring systems that enable rapid neurological assessment within emergency and critical care environments. Earlier seizure identification improves treatment timing while reducing neurological complications. This clinical evolution continues to expand demand for portable EEG platforms and automated monitoring solutions.

Market Restraints

High acquisition and maintenance costs of advanced neurodiagnostic equipment limit adoption among smaller hospitals and resource-constrained healthcare systems. Limited availability of trained epileptologists and EEG technologists restricts efficient utilization of sophisticated diagnostic technologies. Variability in reimbursement policies for advanced neuroimaging, prolonged EEG monitoring, and genetic testing slows widespread clinical adoption. Additionally, the complexity of integrating new diagnostic technologies with existing hospital information systems can present operational hurdles.

Technology and Segment Insights

By Product

Electroencephalography (EEG) systems form the foundation of epilepsy diagnosis, directly measuring abnormal electrical activity associated with epileptic seizures. Demand is increasing as hospitals expand continuous EEG monitoring to improve detection of focal and non-convulsive seizures. Manufacturers are integrating artificial intelligence and automated waveform analysis into modern EEG platforms. Portable and wireless EEG systems are supporting broader adoption across emergency departments and outpatient neurology clinics. Magnetic resonance imaging (MRI) remains essential for identifying structural brain abnormalities, while computed tomography (CT), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) provide complementary functional and anatomical information. Magnetoencephalography (MEG) offers advanced localization capabilities for presurgical evaluation. Molecular and genetic diagnostic tests are becoming increasingly important for identifying inherited epileptic syndromes. Wearable and ambulatory monitoring devices are enabling extended patient observation outside traditional hospital environments.

By Diagnostic Technology

Neuroimaging plays a fundamental role in epilepsy diagnosis by identifying structural and functional brain abnormalities that contribute to seizure disorders. Demand is increasing as clinicians rely on high-resolution imaging to localize epileptogenic lesions, particularly in drug-resistant epilepsy patients. Hospitals are expanding access to advanced MRI, PET, and SPECT technologies to support comprehensive presurgical evaluations. Electrophysiological diagnostics, including routine and continuous EEG, remain the cornerstone of epilepsy diagnosis. Molecular diagnostics are gaining prominence for identifying genetic causes and supporting personalized treatment strategies. Digital and AI-based diagnostics are emerging as transformative technologies, automating seizure detection and improving interpretation efficiency.

By Epilepsy Type

Focal epilepsy represents the largest diagnostic segment because seizures originate within a specific brain region and often require detailed localization before treatment decisions. Neurologists are utilizing multimodal diagnostic approaches to accurately identify seizure onset zones, particularly in patients with drug-resistant epilepsy who may benefit from surgical intervention. Healthcare providers are combining prolonged EEG monitoring with high-resolution MRI, PET, and MEG to improve localization accuracy. Generalized epilepsy, combined generalized and focal epilepsy, and epilepsy of unknown type represent additional segments requiring comprehensive diagnostic evaluation.

By End User

Hospitals represent the largest end-user segment, driven by the need for comprehensive diagnostic services and continuous monitoring capabilities. Neurology clinics are expanding access to EEG and ambulatory monitoring services. Diagnostic imaging centers provide specialized neuroimaging services. Academic and research institutions contribute to innovation and clinical validation of emerging technologies. Ambulatory surgical centers are adopting portable monitoring solutions for outpatient procedures.

Competitive and Strategic Outlook

The competitive landscape features established medical technology companies and specialized neurodiagnostic firms. GE HealthCare combines advanced diagnostic imaging, artificial intelligence, and digital healthcare solutions within an integrated neurological imaging ecosystem. Siemens Healthineers differentiates itself through leadership in advanced neuroimaging technologies and AI-enabled clinical workflows. Koninklijke Philips N.V. maintains a strong position through its comprehensive portfolio of diagnostic imaging systems and connected healthcare solutions. Nihon Kohden Corporation specializes in neurophysiological monitoring technologies, particularly EEG systems. Natus Medical Incorporated focuses on neurodiagnostic and neurological monitoring solutions. Compumedics Limited provides specialized EEG and long-term monitoring technologies. Cadwell Industries, Inc. offers electrophysiological diagnostic systems for neurology and epilepsy laboratories. Masimo Corporation is expanding digital health capabilities that support neurological assessment in acute care environments.
Strategic developments include increasing integration of artificial intelligence into diagnostic platforms, expansion of cloud-based neurology solutions, and development of portable monitoring technologies for decentralized epilepsy care. Companies are forming partnerships with healthcare institutions and research organizations to validate emerging technologies and accelerate commercialization. The market is shifting toward integrated diagnostic ecosystems that combine hardware, software, and digital health services into scalable, interoperable platforms.

Conclusion

The epilepsy diagnostics market is poised for substantial growth, driven by the rising global burden of epilepsy, technological advancements in AI and precision medicine, and increasing emphasis on early diagnosis. The shift toward integrated diagnostic ecosystems combining electrophysiological monitoring, neuroimaging, molecular diagnostics, and AI-powered analytics is reshaping clinical practice. Manufacturers are focusing on portable, interoperable, and intelligent solutions that address specialist shortages and improve healthcare access. Companies that successfully combine diagnostic hardware, intelligent software, and digital health services are expected to strengthen their market position. Ongoing regulatory support and investments in neurological infrastructure across emerging economies will further accelerate innovation and market adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Epilepsy Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Epilepsy Disease Overview
3.3 Evolution of Epilepsy Diagnostics
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Disease Classification
3.8 Epidemiology and Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Diagnostic Pathway and Clinical Workflow
3.11 Current Diagnostic Landscape and Unmet Clinical Needs

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Artificial Intelligence Integration in Epilepsy Diagnostics
6.6 Digital Health Integration
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Epilepsy Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Diagnostic Modality
8.3 Analysis by Biomarker Type
8.4 Analysis by Sample Type
8.5 Analysis by Clinical Application
8.6 Analysis by Testing Methodology

9. Global Epilepsy Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Electroencephalography (EEG) Systems
- 9.1.2 Magnetic Resonance Imaging (MRI)
- 9.1.3 Computed Tomography (CT)
- 9.1.4 Positron Emission Tomography (PET)
- 9.1.5 Single-Photon Emission Computed Tomography (SPECT)
- 9.1.6 Magnetoencephalography (MEG)
- 9.1.7 Molecular & Genetic Diagnostic Tests
- 9.1.8 Wearable and Ambulatory Monitoring Devices
9.2 By Diagnostic Technology
- 9.2.1 Neuroimaging
- 9.2.2 Electrophysiological Diagnostics
- 9.2.3 Molecular Diagnostics
- 9.2.4 Digital & AI-Based Diagnostics
9.3 By Epilepsy Type
- 9.3.1 Focal Epilepsy
- 9.3.2 Generalized Epilepsy
- 9.3.3 Combined Generalized and Focal Epilepsy
- 9.3.4 Unknown Epilepsy
9.4 By Age Group
- 9.4.1 Pediatric
- 9.4.2 Adult
- 9.4.3 Geriatric
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Neurology Clinics
- 9.5.3 Diagnostic Imaging Centers
- 9.5.4 Academic & Research Institutes
- 9.5.5 Ambulatory Surgical Centers